Speaker Profile
Ph.D., Chief Scientific Officer, Nucleix
Biography
Dr. Catherine Schnabel brings over 20 years of scientific and leadership experience in the biomedical and molecular diagnostics industries. Prior to joining Nucleix, Cathy was the Chief Scientific Officer of Biotheranostics, where she led the development and translation of proprietary molecular signatures for breast cancer and metastatic disease, including incorporation of these novel technologies into clinical practice guidelines. An industry leader in evidencebased diagnostics, she has authored over 100 peerreviewed publications and disclosures and is an inventor on several patents. Cathy previously held research positions at Genentech, Genoptix and Amylin Pharmaceuticals, where she investigated and launched firstinclass therapies and biomarkers. Cathy holds a Ph.D. in cell and developmental biology from the Center for Advanced Biotechnology and Medicine at Rutgers University and was a fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University.
Talk
Clinical Dx Showcase:
Nucleix
Nucleix is a liquid biopsy company revolutionizing early cancer detection and recurrence monitoring through its pioneering methylation based EpiCheck technology. Construction of its NGS Lung Cancer Atlas focused on stage I disease will provide a high-resolution platform to discover novel, multi-omic biomarkers for cancer screening.
Epigenetic Detection of Early-stage Lung Cancer
Advancing liquid biopsy tests to detect cancer earlier for better outcomes for patients.
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
